OneAscent Financial Services LLC Has $998,000 Stock Holdings in Eli Lilly and Company $LLY

OneAscent Financial Services LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 75.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,308 shares of the company’s stock after selling 3,964 shares during the quarter. OneAscent Financial Services LLC’s holdings in Eli Lilly and Company were worth $998,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Spirepoint Private Client LLC grew its position in shares of Eli Lilly and Company by 4.3% in the 3rd quarter. Spirepoint Private Client LLC now owns 16,852 shares of the company’s stock valued at $12,858,000 after purchasing an additional 696 shares during the period. Gladstone Institutional Advisory LLC lifted its stake in Eli Lilly and Company by 9.0% in the third quarter. Gladstone Institutional Advisory LLC now owns 20,931 shares of the company’s stock valued at $15,970,000 after buying an additional 1,727 shares in the last quarter. Augustine Asset Management Inc. boosted its holdings in shares of Eli Lilly and Company by 2.7% in the third quarter. Augustine Asset Management Inc. now owns 1,273 shares of the company’s stock valued at $971,000 after buying an additional 33 shares during the period. Community Trust & Investment Co. increased its position in shares of Eli Lilly and Company by 2.0% during the third quarter. Community Trust & Investment Co. now owns 24,067 shares of the company’s stock worth $18,363,000 after acquiring an additional 478 shares in the last quarter. Finally, Autumn Glory Partners LLC raised its holdings in shares of Eli Lilly and Company by 60.7% during the third quarter. Autumn Glory Partners LLC now owns 1,678 shares of the company’s stock worth $1,280,000 after acquiring an additional 634 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 4.1%

Shares of Eli Lilly and Company stock opened at $1,107.54 on Thursday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,117.66. The stock has a market cap of $1.05 trillion, a P/E ratio of 54.18, a P/E/G ratio of 0.77 and a beta of 0.35. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The business’s 50 day moving average is $1,028.26 and its 200-day moving average is $856.98.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s revenue was up 53.9% on a year-over-year basis. During the same period last year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 33.86%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. UBS Group started coverage on shares of Eli Lilly and Company in a research note on Tuesday. They issued a “buy” rating and a $1,250.00 target price for the company. Morgan Stanley boosted their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Five research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Buy” and an average price target of $1,169.00.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly confirmed it will buy Ventyx Biosciences in an all-cash deal worth about $1.2 billion, gaining a pipeline of oral small-molecule NLRP3 inhibitors and inflammatory disease candidates that expand Lilly beyond diabetes/weight-loss. This acquisition is a clear pipeline/strategic positive. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Positive Sentiment: Lilly expanded its obesity/metabolic pipeline via a multiyear partnership/licensing deal with Nimbus (reported value ~$1.3B), adding an oral obesity candidate to its development portfolio — another growth pathway beyond injectables. Boston biotech Nimbus to partner with Eli Lilly on weight-loss pill in $1.3 billion deal
• Positive Sentiment: Lilly struck a collaboration with InduPro on a next-gen cancer program worth up to $950 million, strengthening oncology exposure and long-term revenue optionality. Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
• Positive Sentiment: Clarivate named several Lilly cardiometabolic launches among drugs to watch for 2026, highlighting continued product catalysts beyond current blockbusters. Lilly’s prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate
• Positive Sentiment: Analysts are bullish: Citigroup flagged ~50% upside, and several upgrades/positive notes have circulated, supporting momentum and investor confidence in Lilly’s pipeline and earnings outlook. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Neutral Sentiment: The stock printed an all-time high intraday as buyers priced in the M&A and deal flow; that’s market confirmation of the reaction but not a new fundamental. Eli Lilly stock hits all-time high of 1113.03 USD
• Negative Sentiment: Lilly faces legal pressure: the Indiana attorney general sued alleging inflated insulin pricing, a regulatory and reputational overhang that could lead to fines, settlements or policy scrutiny. Indiana sues Eli Lilly alleging insulin price-fixing scheme

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.